D E Tsai

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia
    Donald E Tsai
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Leuk Lymphoma 45:591-5. 2004
  2. doi request reprint EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial
    D E Tsai
    Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Am J Transplant 8:1016-24. 2008
  3. doi request reprint A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia
    Donald E Tsai
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 14:5619-25. 2008
  4. ncbi request reprint Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody
    Donald E Tsai
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, 19104, USA
    Clin Lymphoma 4:56-9. 2003
  5. ncbi request reprint Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene
    Donald E Tsai
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
    Am J Transplant 5:2070-3. 2005
  6. ncbi request reprint Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene
    Donald E Tsai
    Hematology Oncology Division, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Cancer Biol Ther 6:18-21. 2007
  7. ncbi request reprint Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients
    Donald E Tsai
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Am J Transplant 2:946-54. 2002
  8. ncbi request reprint Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder
    Donald E Tsai
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Clin Transplant 19:644-52. 2005
  9. ncbi request reprint Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy
    D E Tsai
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Clin Lymphoma 1:62-6. 2000
  10. ncbi request reprint Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients
    D E Tsai
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    Transplantation 71:1076-88. 2001

Detail Information

Publications43

  1. ncbi request reprint Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia
    Donald E Tsai
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Leuk Lymphoma 45:591-5. 2004
    ..The patient had a complete response to the treatment, including disappearance of any detectable IgM paraprotein. This case report demonstrates the potential for radioimmunotherapy in CD20 positive B-cell malignancies...
  2. doi request reprint EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial
    D E Tsai
    Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Am J Transplant 8:1016-24. 2008
    ..We conclude that EBV PCR is a useful test for managing PTLD patients. While plasma EBNA PCR is the best single assay for diagnosing and monitoring PTLD, the complete PCR panel is superior for ruling out its presence...
  3. doi request reprint A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia
    Donald E Tsai
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 14:5619-25. 2008
    ..We therefore conducted a phase I dose escalation study to assess the maximum tolerated dose, toxicities, and activity of bexarotene in patients with non-M3 acute myeloid leukemia (AML)...
  4. ncbi request reprint Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody
    Donald E Tsai
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, 19104, USA
    Clin Lymphoma 4:56-9. 2003
    ..This case report demonstrates the potential for repeated treatments with radioimmunotherapy agents in patients with chemotherapy-refractory non-Hodgkin's lymphoma...
  5. ncbi request reprint Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene
    Donald E Tsai
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
    Am J Transplant 5:2070-3. 2005
    ..The patient was successfully treated with bexarotene, a novel synthetic retinoid analog, achieving a complete clinical response. Bexarotene may be a promising treatment for T-cell PTLD...
  6. ncbi request reprint Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene
    Donald E Tsai
    Hematology Oncology Division, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Cancer Biol Ther 6:18-21. 2007
    ..These data suggest that bexarotene has clinical activity in non-M3 AML and may be able to induce myeloid differentiation in vivo...
  7. ncbi request reprint Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients
    Donald E Tsai
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Am J Transplant 2:946-54. 2002
    ..We conclude that peripheral blood EBV PCR may have a role in the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients...
  8. ncbi request reprint Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder
    Donald E Tsai
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Clin Transplant 19:644-52. 2005
    ..68 wk, p = 0.003). Persistence of MG after complete response of the PTLD did not predict relapse. There is a high incidence of MG and gammaglobulin abnormalities in patients with PTLD...
  9. ncbi request reprint Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy
    D E Tsai
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Clin Lymphoma 1:62-6. 2000
    ..Both patients achieved a rapid response to the radiolabeled antibody with minimal toxicity. Monoclonal antibody therapy may be an effective and tolerable treatment for progressive NHL after PSCT...
  10. ncbi request reprint Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients
    D E Tsai
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    Transplantation 71:1076-88. 2001
    ..With the increased use of organ transplantation and intensive immunosuppression, this disease is becoming more common. We explore reduction in immunosuppression as an initial therapy for PTLD...
  11. ncbi request reprint Hypertriglyceridemia presenting as "pink blood" and elevated hemoglobin level
    Donald E Tsai
    Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Am J Hematol 83:253. 2008
  12. ncbi request reprint Treatment of PTLD with rituximab or chemotherapy
    R L Elstrom
    Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, USA
    Am J Transplant 6:569-76. 2006
    ..PTLD patients requiring therapy beyond RI should be considered for rituximab, especially with EBV-positive disease. Chemotherapy should be reserved for patients who fail rituximab, have EBV-negative tumors or need a rapid response...
  13. ncbi request reprint Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma
    C Andreadis
    Bone Marrow and Stem Cell Transplantation Program and Lymphoma Program, The Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, 19104, USA
    Bone Marrow Transplant 36:955-61. 2005
    ..ASCT is thus a safe therapeutic approach in FL, resulting in long-term EFS and OS for some patients, even with transformed disease...
  14. pmc Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma
    R L Olin
    Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 43:417-22. 2009
    ..We conclude that in well-selected patients, salvage auto-SCT is safe and effective for relapsed myeloma...
  15. ncbi request reprint Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases
    Himisha Patel
    Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Leuk Lymphoma 48:885-91. 2007
    ..Although detection and treatment of PTLD in liver transplant recipients remains problematic and upfront mortality is still high, long-term survival is possible. Further studies are necessary to better define treatment strategies...
  16. ncbi request reprint Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination
    E A Stadtmauer
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    Med Oncol 16:279-88. 1999
    ....
  17. ncbi request reprint Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation
    A W Loren
    Bone Marrow and Stem Cell Transplant Programs, University of Pennsylvania Cancer Center, Philadelphia, PA, USA
    Bone Marrow Transplant 35:921-6. 2005
    ..05). The combination of Cs/MMF is inadequate GVHD prophylaxis for UD-NST. The use of Cs, MTX, and alemtuzumab eliminated severe acute GVHD; its impact on response merits further study...
  18. ncbi request reprint Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease
    A D Cohen
    Hematologic Malignancies Program and the Bone Marrow and Stem Cell Transplantation Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 30:23-8. 2002
    ..The other seven patients did not meet diagnostic criteria for VOD. We conclude that GO can be safe and effective in patients who relapse following HSCT, but that caution is warranted in patients with multiple risk factors for VOD...
  19. ncbi request reprint The management of posttransplant lymphoproliferative disorder
    Noelle V Frey
    University of Pennsylvania Cancer Center, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Med Oncol 24:125-36. 2007
    ..Further investigations are needed to better define the role of more novel and less widely available therapies such as the adoptive transfer of EBV-specific T cells and optimization of antiviral therapies...
  20. ncbi request reprint Successful treatment of relapsed lymphomatoid granulomatosis with bexarotene
    Sigrid E Berg
    Abramson Cancer Center, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, PA 19104, USA
    Cancer Biol Ther 7:1544-6. 2008
    ..We present a case of successful treatment of relapsed lymphomatoid granulomatosis with bexarotene, a novel retinoid agent...
  21. pmc Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★)
    R Reshef
    Abramson Cancer Center Department of Biostatistics and Epidemiology Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Am J Transplant 11:336-47. 2011
    ..Patients with none or one of these factors had a 3-year overall survival of 100% and 79%, respectively. These findings support the use of RI alone in low-risk PTLD and suggest factors that predict response and survival...
  22. doi request reprint A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
    Alexander E Perl
    Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 15:6732-9. 2009
    ..We sought to determine the safety and describe the toxicity of this approach by adding the mTOR inhibitor, sirolimus (rapamycin), to intensive AML induction chemotherapy...
  23. ncbi request reprint Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection
    Vivek N Ahya
    Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Heart Lung Transplant 26:839-44. 2007
    ..We investigated the hypothesis that detection of latent Epstein-Barr virus (EBV) in peripheral blood may be a functional marker for the net effects of administered immunosuppression...
  24. ncbi request reprint Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma
    Bradley G Somer
    University of Pennsylvania Cancer Center, Philadelphia, USA
    Arthritis Rheum 49:394-8. 2003
  25. ncbi request reprint Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab
    Jakub Svoboda
    University of Pennsylvania Cancer Center, Bone Marrow and Stem Cell Transplant Program, Philadelphia, 19104, USA
    Transpl Int 19:259-69. 2006
    ..This paper reviews the current data on rituximab and its promising role in the management of PTLD...
  26. ncbi request reprint Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support
    Dan T Vogl
    Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Am J Hematol 82:1071-5. 2007
    ..Future trials comparing induction therapies should examine progression-free and overall survival after transplant to confirm this benefit...
  27. ncbi request reprint Use of serum protein electrophoresis to monitor patients with post-transplant lymphoproliferative disorder
    Nicole A Aqui
    Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    Am J Transplant 3:1308-11. 2003
    ..The amount of M protein paralleled the disease course, decreasing as the clinical symptoms improved. This case illustrates the utility of using SPEP to monitor patients with PTLD...
  28. ncbi request reprint Post-transplant lymphoproliferative disorder: a review
    A W Loren
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 31:145-55. 2003
    ....
  29. doi request reprint Treatment advances in posttransplant lymphoproliferative disease
    Courtney D DiNardo
    Department of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Pennsylvania, Philadelphia 19104, USA
    Curr Opin Hematol 17:368-74. 2010
    ..Several innovative therapeutic approaches are currently under development to add to our arsenal of treatment strategies in this devastating disease...
  30. doi request reprint Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene
    Courtney D DiNardo
    Department of Internal Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Med Oncol 25:299-302. 2008
    ..This case emphasizes the importance of monitoring for differentiation syndrome among patients receiving retinoid therapies and demonstrates the ability of bexarotene to stimulate differentiation of leukemic blasts...
  31. ncbi request reprint A peptide-based inhibitor for prevention of B cell hyperproliferation induced by Epstein-Barr virus
    Jason S Knight
    Department of Microbiology, University of Pennsylvania Medical School, 201E Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
    Virology 354:207-14. 2006
    ..Importantly, the peptide inhibited lymphoblastoid outgrowth from the blood of an EBV-positive transplant patient in vitro...
  32. ncbi request reprint Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow
    Rebecca L Elstrom
    Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, 17104, USA
    Clin Lymphoma 5:62-4. 2004
    ..However, iliac crest bone marrow examination showed marked myeloid hyperplasia without evidence of lymphoma involvement. We discuss the implications for interpretation of FDG-PET imaging of bone marrow in lymphomas...
  33. ncbi request reprint Primary lymphomas of the cervix and uterus: the University of Pennsylvania's experience and a review of the literature
    Noelle V Frey
    Abramson Cancer Center of the Hospital of the University of Pennsylvania, 3400 Spruce, Philadelphia, PA 19104, USA
    Leuk Lymphoma 47:1894-901. 2006
    ..In general, patients with limited stage disease should be treated with localized and systemic therapy to optimize chances of cure...
  34. ncbi request reprint Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy
    Michael C Milone
    Department of Pathology and Laboratory Medicine, Hematologic Malignancies Program, University of Pennsylvania, Philadelphia, USA
    Blood 105:994-6. 2005
    ..These data suggest that the pre-emptive use of B-cell-directed therapy may reduce the morbidity and mortality of primary EBV infection in XLP-affected individuals...
  35. doi request reprint Detection of Epstein-Barr virus in T-cell prolymphocytic leukemia cells in vitro
    Ke Lan
    Department of Microbiology and the Tumor Virology Program of Abramson Comprehensive Cancer Center, University of Pennsylvania Medical School, 201E Johnson Pavilion, Philadelphia, PA 19104, U S
    J Clin Virol 43:260-5. 2008
    ....
  36. ncbi request reprint Regression of pulmonary MALT lymphoma after treatment with rituximab
    Elise A Chong
    Hematology Oncology Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Leuk Lymphoma 46:1383-6. 2005
    ..This case report demonstrates the potential efficacy of rituximab as a single therapeutic agent in patients with pulmonary MALT lymphoma...
  37. ncbi request reprint Removal of gadolinium by peritoneal dialysis
    M Murashima
    Renal Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Nephrol 69:368-72. 2008
    ....
  38. ncbi request reprint Post-transplant lymphoproliferative disorder
    Alison W Loren
    Division of Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Clin Chest Med 26:631-45, vii. 2005
    ..An increasing variety of highly effective therapies, including immune modulation via reduction in immunosuppression, monoclonal antibodies, and cellular therapy, have dramatically improved the cure rates of this once devastating disease...
  39. ncbi request reprint Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation
    Dan T Vogl
    Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA
    Leuk Lymphoma 46:1313-20. 2005
    ..Physicians should be aware of the potential for developing a gemcitabine-induced radiation recall reaction resulting in hemodynamically significant pericardial effusion...
  40. doi request reprint Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case report
    Miho Murashima
    Department of Medicine, Renal Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Am J Kidney Dis 53:871-4. 2009
    ..124 +/- 0.037 mL/min/kg (0.00207 +/- 0.00062 mL/s/kg). Despite lower clearance by means of peritoneal dialysis compared with hemodialysis, the patient did not develop clinical evidence of methotrexate toxicity...
  41. ncbi request reprint Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Robert M Sharkey
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109, USA
    J Nucl Med 44:2000-18. 2003
    ..Of particular interest was to evaluate whether pretherapy targeting and tumor dosimetry could predict therapeutic responses...
  42. ncbi request reprint Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma
    John P Leonard
    Weill Medical College of Cornell University, New York, New York, USA
    Clin Cancer Res 13:6168-74. 2007
    ..This Phase I trial was designed to investigate the safety, tolerability, and preliminary antitumor activity of PF-3512676 in combination with rituximab...
  43. ncbi request reprint Posttransplant lymphoproliferative disorder
    Matthew J Everly
    University of Cincinnati, Cincinnati, OH 45267, USA
    Ann Pharmacother 41:1850-8. 2007
    ..To define and discuss the pathogenesis, clinical presentation, diagnosis, risk factors, and current preventive and treatment strategies of posttransplant lymphoproliferative disorder (PTLD)...